Filtered By:
Condition: Hemorrhagic Stroke
Procedure: Lung Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Medtronic touts stroke data for HeartWare LVAD
A retrospective analysis of two studies involved the HeartWare left-ventricular assist device Medtronic (NYSE:MDT) acquired in 2016 showed that managing blood pressure reduced the severity of strokes in patients implanted with the HVAD pump. The analysis, of “destination therapy” patients who are not candidates for a heart transplant, took data from the Endurance and Endurance Supplemental studies. Results were presented this week at the annual meeting of the International Society for Heart & Lung Transplantation in London, Medtronic said. The 465-patient Endurance Supplemental study compared 308 patients i...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Abbott HeartWare International Inc. Medtronic stjudemedical Thoratec Corp. Source Type: news

ISHLT 2017: Medtronic HVAD trial misses primary endpoint, reports lowered stroke rates
Medtronic (NYSE:MDT) said today that results from the Endurance supplemental trial of its HVAD heart pump system did not meet its primary endpoint, but did report  lowered stroke rates compared to standard treatment. The trial aimed to evaluate the use of the HVAD system, which it picked up along with HeartWare last year, as a destination therapy for patients who require a left ventricular assist device and received improved blood pressure management, the Fridley, Minn.-based company said. Data from the study was presented at the 2017 International Society for Heart and Lung Transplantation Scientific Meeting in San Dieg...
Source: Mass Device - April 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials HeartWare International Inc. Medtronic Source Type: news

Blood pressure and stroke risk in left ventricular assist devices
Ischemic and hemorrhagic stroke are one of the most devastating outcomes arising from treatment of end-stage congestive heart failure with a left ventricular assist device (LVAD)1. Stroke after LVAD is associated with increased risk of mortality and is a leading cause of not qualifying for transplantation. The risk of stroke is one of many factors limiting more widespread adoption of this technology for end-stage heart failure. The risk factors for stroke in LVAD have been the subject of several studies, with recent infection2 and changes in anti-thrombotics being commonly found3.
Source: The Journal of Heart and Lung Transplantation - December 5, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey Source Type: research

Successful Bridge From Va-Ecmo to Heart Transplant in an Adult after Mechanical Thrombectomy for Acute Ischemic Stroke
We present a unique case of a patient who underwent MT for acute ischemic stroke while on VA-ECMO with the resolution of neurological deficits and eventually underwent heart transplantation (HT).
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: S. Riaz, M. Hakim, T.V. Mehta, A. Jaiswal, A. Scatola Tags: (777) Source Type: research

Anticoagulation Reversal With 4-Factor Prothrombin Complex Concentrate in Left Ventricular Assist Device Patients With Acute Hemorrhagic Stroke
Anticoagulation reversal in patients with left ventricular assist devices (LVAD) after acute hemorrhagic stroke must occur rapidly to prevent hemorrhage expansion and limit neurologic sequelae, keeping in mind the risk of thrombotic complications. The purpose of this study was to report a case series of our initial experience using a recently FDA approved (April 2013) 4-factor prothrombin complex concentrate (4F-PCC) for INR normalization after acute hemorrhagic stroke in LVAD patients, and compare the results with traditional INR reversal agents.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: P. Chen, J. Falvey, L. Lowenstein, A. Miranpuri, W. Hallinan, T. Massey Source Type: research

Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support
Patients with end-stage heart failure on left ventricular assist devices are predisposed to stroke. Preoperative factors associated with increased stroke risk are poorly understood.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: H.K. Lamba, M. Kim, L. Hart, B. Chou, C. Rao, S. Chatterjee, S. Sattee, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan Tags: 402 Source Type: research

Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices
The ENDURANCE Supplemental Trial (DT2) was designed to prospectively study whether improved blood pressure management would reduce the incidence of strokes in destination therapy patients receiving an HVAD. The trial not only demonstrated a significant reduction in hemorrhagic strokes, but also some reductions in stroke-related severity. This analysis seeks to study further the impact of stroke severity on 2-year survival in both the HVAD and control cohorts of DT2.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: P. Shah, C. Mahr, J. Rogers, M. Kiernan, S. Boyce, N.A. Mokadam, F. Pagani, T. Vassiliades, J. Teuteberg Tags: 145 Source Type: research

Understanding Risk Factors for Stroke Subtypes in the ENDURANCE Trials
Stroke is one of the most devastating morbidities associated with left ventricular assist device (LVAD) support. Improved blood pressure management in LVAD patients has been shown to significantly reduce strokes, in particular hemorrhagic strokes. However, little is known regarding clinical risk factors for stroke subtypes.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S. Cho, R. Starling, J. Teuteberg, J. Rogers, F. Pagani, P. Shah, K. Uchino, T. Vassiliades Tags: 142 Source Type: research

CHA2DS2-Vasc and HAS-BLED Scores as Predictors of Ischemic and Hemorrhagic Stroke Risk After Left Ventricular Assist Device Implantation
CHA2DS2-VASc score predicts thromboembolic event risk and HAS-BLED score predicts major bleeding risk in patients on anticoagulation with atrial fibrillation. We aimed to evaluate if these scoring systems would be predictive of ischemic stroke and intracranial bleeding complications following continuous-flow left ventricular assist device (CF-LVAD) implantation.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: H.S. Kemal, S. Ertugay, S. Nalbantgil, M. Zoghi, C. Engin, T. Yagdi, M. Ozbaran Source Type: research

Risk Factors, Mortality and Timing of Ischemic and Hemorrhagic Stroke with Left Ventricular Assist Devices
Stroke is a major cause of mortality following left ventricular assist device (LVAD) placement.
Source: The Journal of Heart and Lung Transplantation - December 22, 2016 Category: Transplant Surgery Authors: Jennifer A. Frontera, Randall Starling, Sung-Min Cho, Amy S. Nowacki, Ken Uchino, M. Shazam Hussain, Maria Mountis, Nader Moazami Tags: Original Clinical Science Source Type: research

Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices
Stroke is a major cause of mortality after left ventricular assist device (LVAD) placement.
Source: The Journal of Heart and Lung Transplantation - December 22, 2016 Category: Transplant Surgery Authors: Jennifer A. Frontera, Randall Starling, Sung-Min Cho, Amy S. Nowacki, Ken Uchino, M. Shazam Hussain, Maria Mountis, Nader Moazami Tags: Original Clinical Science Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events
Background: The aim of this study was to evaluate the prevalence of early pump power elevation events in patients with the HeartMate II (HMII) and its impact on subsequent development of stroke and pump thrombosis.Methods: We analyzed>45,000 measurements of pump power and pump speed measured during the initial hospitalization period and>12,000 follow-up measurements obtained from 138 consecutive patients implanted with a HMII between January 2009 and December 2012. An early power elevation (PEL) event was defined as power ≥10 W within the first 14 post-operative days. Patients were divided into two groups: those with an ...
Source: The Journal of Heart and Lung Transplantation - March 3, 2014 Category: Transplant Surgery Authors: Christopher T. Salerno, Kartik S. Sundareswaran, Thomas P. Schleeter, Sina L. Moanie, David J. Farrar, Mary Norine Walsh Tags: Featured Articles Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news